Rhodes Jason P's Form 4 filing
Dyne Therapeutics, Inc.DYN · filed Apr 27, 2026
- Accession no.
- 0001577014-26-000004
- Filed
- Apr 27, 2026
- Trade date
- Apr 23-27, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 12 non-derivative transactions. Open-market sales total $7.10M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rhodes Jason PCIK 0001577014 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Common Stock | SSaleDisposed | −19,261 | $19.19F2 | −$369,618.59 | 1,719,356 | Indirect | |
| Apr 23, 2026 | Common Stock | SSaleDisposed | −38,322 | $19.19F2 | −$735,399.18 | 5,221,857 | Indirect | |
| Apr 23, 2026 | Common Stock | SSaleDisposed | −377 | $19.19F2 | −$7,234.63 | 11,286 | Indirect | |
| Apr 23, 2026 | Common Stock | SSaleDisposed | −15,148 | $19.19F2 | −$290,690.12 | 1,270,556 | Indirect | |
| Apr 24, 2026 | Common Stock | SSaleDisposed | −36,345 | $18.48F7 | −$671,655.6 | 1,683,011 | Indirect | |
| Apr 24, 2026 | Common Stock | SSaleDisposed | −72,310 | $18.48F7 | −$1,336,288.8 | 5,149,547 | Indirect | |
| Apr 24, 2026 | Common Stock | SSaleDisposed | −710 | $18.48F7 | −$13,120.8 | 10,576 | Indirect | |
| Apr 24, 2026 | Common Stock | SSaleDisposed | −28,583 | $18.48F7 | −$528,213.84 | 1,241,973 | Indirect | |
| Apr 27, 2026 | Common Stock | SSaleDisposed | −45,709 | $18.15F8 | −$829,618.35 | 1,637,302 | Indirect | |
| Apr 27, 2026 | Common Stock | SSaleDisposed | −90,943 | $18.15F8 | −$1,650,615.45 | 5,058,604 | Indirect | |
| Apr 27, 2026 | Common Stock | SSaleDisposed | −894 | $18.15F8 | −$16,226.1 | 9,682 | Indirect | |
| Apr 27, 2026 | Common Stock | SSaleDisposed | −35,947 | $18.15F8 | −$652,438.05 | 1,206,026 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 4 transactions in Table I.
- F7
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 4 transactions in Table I.
- F8
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 4 transactions in Table I.